Fate therapeutics announces clinical safety and activity data of first-ever ipsc-derived car t-cell therapy at 2022 ash annual meeting

Ft819 off-the-shelf car t-cell product candidate derived from clonal engineered master ipsc line with novel cd19-specific 1xx car integrated into trac locus

FATE Ratings Summary

FATE Quant Ranking